These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

539 related items for PubMed ID: 29427492

  • 1. Future therapy for non-alcoholic fatty liver disease.
    Issa D, Patel V, Sanyal AJ.
    Liver Int; 2018 Feb; 38 Suppl 1():56-63. PubMed ID: 29427492
    [Abstract] [Full Text] [Related]

  • 2.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 3. Therapies in non-alcoholic steatohepatitis (NASH).
    Oseini AM, Sanyal AJ.
    Liver Int; 2017 Jan; 37 Suppl 1(Suppl 1):97-103. PubMed ID: 28052626
    [Abstract] [Full Text] [Related]

  • 4. Nonalcoholic fatty liver disease: a systematic review.
    Rinella ME.
    JAMA; 2015 Jun 09; 313(22):2263-73. PubMed ID: 26057287
    [Abstract] [Full Text] [Related]

  • 5. Treatment Strategies for Nonalcoholic Fatty Liver Disease and Nonalcoholic Steatohepatitis.
    Golabi P, Bush H, Younossi ZM.
    Clin Liver Dis; 2017 Nov 09; 21(4):739-753. PubMed ID: 28987260
    [Abstract] [Full Text] [Related]

  • 6. Will Studies in Nonalcoholic Steatohepatitis Help Manage Alcoholic Steatohepatitis?
    Sundaram V, Morgan TR.
    Clin Liver Dis; 2019 Feb 09; 23(1):157-165. PubMed ID: 30454829
    [Abstract] [Full Text] [Related]

  • 7. Current and Emerging Therapies for Non-alcoholic Fatty Liver Disease.
    Patel SS, Siddiqui MS.
    Drugs; 2019 Jan 09; 79(1):75-84. PubMed ID: 30588564
    [Abstract] [Full Text] [Related]

  • 8. The therapeutic landscape of non-alcoholic steatohepatitis.
    Perazzo H, Dufour JF.
    Liver Int; 2017 May 09; 37(5):634-647. PubMed ID: 27727520
    [Abstract] [Full Text] [Related]

  • 9. The use of statins alone, or in combination with pioglitazone and other drugs, for the treatment of non-alcoholic fatty liver disease/non-alcoholic steatohepatitis and related cardiovascular risk. An Expert Panel Statement.
    Athyros VG, Alexandrides TK, Bilianou H, Cholongitas E, Doumas M, Ganotakis ES, Goudevenos J, Elisaf MS, Germanidis G, Giouleme O, Karagiannis A, Karvounis C, Katsiki N, Kotsis V, Kountouras J, Liberopoulos E, Pitsavos C, Polyzos S, Rallidis LS, Richter D, Tsapas AG, Tselepis AD, Tsioufis K, Tziomalos K, Tzotzas T, Vasiliadis TG, Vlachopoulos C, Mikhailidis DP, Mantzoros C.
    Metabolism; 2017 Jun 09; 71():17-32. PubMed ID: 28521870
    [Abstract] [Full Text] [Related]

  • 10. Challenges and Management of Liver Cirrhosis: Practical Issues in the Therapy of Patients with Cirrhosis due to NAFLD and NASH.
    Traussnigg S, Kienbacher C, Halilbasic E, Rechling C, Kazemi-Shirazi L, Hofer H, Munda P, Trauner M.
    Dig Dis; 2015 Jun 09; 33(4):598-607. PubMed ID: 26159280
    [Abstract] [Full Text] [Related]

  • 11.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 12.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 13. [Prognosis and treatment of non-alcoholic fatty liver disease and steatohepatitis].
    Heebøll S, Kazankov K, Poulsen MK, Vilstrup H, Grønbæk H.
    Ugeskr Laeger; 2012 Feb 20; 174(8):488-90. PubMed ID: 22348670
    [Abstract] [Full Text] [Related]

  • 14.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 15. State of the art: treatment of nonalcoholic steatohepatitis.
    Pearlman M, Loomba R.
    Curr Opin Gastroenterol; 2014 May 20; 30(3):223-37. PubMed ID: 24717764
    [Abstract] [Full Text] [Related]

  • 16.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 17.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 18.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 19.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 20.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 27.